[go: up one dir, main page]

WO2011060944A3 - Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters - Google Patents

Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters Download PDF

Info

Publication number
WO2011060944A3
WO2011060944A3 PCT/EP2010/007024 EP2010007024W WO2011060944A3 WO 2011060944 A3 WO2011060944 A3 WO 2011060944A3 EP 2010007024 W EP2010007024 W EP 2010007024W WO 2011060944 A3 WO2011060944 A3 WO 2011060944A3
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
polyunsaturated fatty
active pharmaceutical
acid esters
pharmaceutical ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/007024
Other languages
French (fr)
Other versions
WO2011060944A2 (en
WO2011060944A8 (en
Inventor
Antonio PARENTE DUEÑA
Paolo Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GP Pharm SA
Defiante Farmaceutica SA
Original Assignee
GP Pharm SA
Defiante Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GP Pharm SA, Defiante Farmaceutica SA filed Critical GP Pharm SA
Publication of WO2011060944A2 publication Critical patent/WO2011060944A2/en
Publication of WO2011060944A8 publication Critical patent/WO2011060944A8/en
Publication of WO2011060944A3 publication Critical patent/WO2011060944A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical composition in the form of a capsule which contains alkyl esters of polyunsaturated fatty acid (PUFA) and active pharmaceutical ingredients for the treatment and/or prevention of cardiovascular diseases and/or inflammatory processes.
PCT/EP2010/007024 2009-11-20 2010-11-19 Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters Ceased WO2011060944A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931026A ES2363964B1 (en) 2009-11-20 2009-11-20 CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
ES200931026 2009-11-20

Publications (3)

Publication Number Publication Date
WO2011060944A2 WO2011060944A2 (en) 2011-05-26
WO2011060944A8 WO2011060944A8 (en) 2011-10-27
WO2011060944A3 true WO2011060944A3 (en) 2012-05-03

Family

ID=43498493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/007024 Ceased WO2011060944A2 (en) 2009-11-20 2010-11-19 Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters

Country Status (4)

Country Link
AR (1) AR079429A1 (en)
ES (1) ES2363964B1 (en)
TW (1) TW201141470A (en)
WO (1) WO2011060944A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (en) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
ITMI20112221A1 (en) * 2011-12-05 2013-06-06 Altergon Sa STABLE FORMULATIONS IN JELLY CAPSULES SPRINGS OF PIASTRINICAL ANTI-AGGREGATES, OMEGA-3 FATTY ACIDS AND AMYLOSUS
EP2836206A4 (en) * 2012-04-10 2015-11-04 Rubicon Res Private Ltd Controlled release pharmaceutical formulations of direct thrombin inhibitors
WO2014007780A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
WO2014007779A1 (en) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally-disintegrating formulations of dexketoprofen
CN103626689B (en) * 2012-08-24 2016-03-09 上海医药工业研究院 A kind of preparation method of intermediate of Eliquis
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
CN106620707B (en) * 2017-03-14 2019-06-07 牡丹江医学院 A kind of pharmaceutical composition and its preparation method and application preventing and treating myocardial ischemia
AR115269A1 (en) 2018-03-15 2020-12-16 Scherer Technologies Llc R P ENTERIC SOFT GELATINE CAPSULES
CN114869857B (en) * 2022-05-12 2023-04-04 郑州大学第一附属医院 Argatroban particles, preparation and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils
EP1803440A1 (en) * 2004-10-19 2007-07-04 GP Pharm S.A. Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa)
US20070196465A1 (en) * 2005-07-28 2007-08-23 George Bobotas Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (en) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS5920230A (en) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト Drug containing piruprophen
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US4954346A (en) 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
FR2660555B1 (en) 1990-04-06 1994-09-16 Rhone Poulenc Sante KETOPROFEN OIL CAPSULE.
ES2071986T3 (en) 1990-04-11 1995-07-01 Upjohn Co MASKING THE FLAVOR OF IBUPROPHEN WITH A FLUIDIFIED BED COATING.
CA2039742A1 (en) 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
RU2148402C1 (en) 1994-03-15 2000-05-10 Сендзю Фармасьютикал Ко., Лтд. Method of stabilization of pranoprofen (variants) and pranoprofen-base stable aqueous preparation
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
EP0839029A1 (en) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
WO1997033568A1 (en) 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
JP2003509453A (en) 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド Surface-modified granular compositions of biologically active substances
DE10026699A1 (en) 2000-05-30 2001-12-06 Basf Ag Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
ES2240492T3 (en) 2000-08-25 2005-10-16 Kowa Company, Ltd. IBUPROFEN SOLUTIONS TO FILL CAPSULES AND CAPSULES PREPARATIONS.
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6673944B2 (en) 2001-02-28 2004-01-06 Taro Pharmaceutical Industries, Ltd. Preparation of warfarin sodium from warfarin acid
ITFI20020144A1 (en) 2002-08-01 2004-02-02 Menarini Farma Ind STABILIZED TOPICAL FORMULATIONS CONTAINING KETOPROFENE.
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
WO2005051383A1 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
US20080311207A1 (en) 2004-09-08 2008-12-18 Manoj Varshney Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
US20080095841A1 (en) 2004-10-06 2008-04-24 Eisai R&D Management Co., Ltd. Pharmaceutical Composition, Method for Producing the Same, and Method for Stabilizing Dihydropyridine Compound in the Pharmaceutical Composition
CA2596035A1 (en) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
EP1688129B1 (en) 2005-02-02 2015-07-08 Omega Pharma Nordic AB New therapeutic formulation
JP5273721B2 (en) * 2005-03-21 2013-08-28 ビカス セラピューティクス，エルエルシー Compositions and methods for mitigating cachexia
JP5628480B2 (en) * 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー Coated capsule containing pharmaceutical ingredients
KR100913791B1 (en) 2006-07-21 2009-08-26 한미약품 주식회사 (S)-(-)-amlodipine camsylate or a hydrate thereof and a pharmaceutical composition containing the same
WO2008062435A2 (en) 2006-08-15 2008-05-29 Alkem Laboratories Ltd. Stabilised dosage forms of amlodipine besylate
EP1894561A1 (en) 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Dipyridamole pharmaceutical compositions
ATE498626T1 (en) 2006-09-25 2011-03-15 Adamed Sp Zoo NEW CLOPIDOGREL SALT AND ITS CRYSTALLINE FORMS
MX2009003928A (en) 2006-10-13 2009-09-21 Reliant Pharmaceuticals Inc Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof.
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
WO2008070950A1 (en) 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
KR20080055356A (en) 2006-12-15 2008-06-19 에스케이케미칼주식회사 Clopidogrel-containing clathrate composite with excellent storage stability
JP2010515773A (en) 2007-01-16 2010-05-13 リライアント・ファーマシューティカルズ・インコーポレイテッド Treatment with non-steroidal anti-inflammatory drugs and omega-3 fatty acids and combination products thereof
RU2009140792A (en) 2007-04-09 2011-05-20 Юсв Лимитед (In) NEW STABLE PHARMACEUTICAL COMPOSITIONS BISULPHATE CLOPIDOGEL AND METHOD FOR PRODUCING THEM

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils
EP1803440A1 (en) * 2004-10-19 2007-07-04 GP Pharm S.A. Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa)
US20070196465A1 (en) * 2005-07-28 2007-08-23 George Bobotas Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions

Also Published As

Publication number Publication date
WO2011060944A2 (en) 2011-05-26
ES2363964B1 (en) 2012-08-22
TW201141470A (en) 2011-12-01
ES2363964A1 (en) 2011-08-22
WO2011060944A8 (en) 2011-10-27
AR079429A1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
WO2009091538A3 (en) Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia
NZ734905A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP4338805A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2011128635A3 (en) Anti-abuse pharmaceutical compositions
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
IL210233A (en) Omega-3 fatty acid formulations containing epa and dha and no active ingredients other than omega-3 fatty acids
ZA201202263B (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ595204A (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
NZ600721A (en) Capsule formulation
HK1198515A1 (en) Fatty acid compositions
EP2506848A4 (en) Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
GB2459809A (en) Fatty acid formulations and methods of use thereof
WO2010129565A3 (en) Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
MX2016004487A (en) Enteric soft capsules comprising polyunsaturated fatty acids.
HUE050830T2 (en) Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
WO2007090408A3 (en) Coated tablets, their methods of preparation, and related uses
GEP20125464B (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
EP2560633B8 (en) Intravenous omega-3 fatty acid compositions & method of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788004

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10788004

Country of ref document: EP

Kind code of ref document: A2